NOTV
Inotiv, Inc. [NOTV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NOTV Stock Summary
Top NOTV Correlated Resources
NOTV
Top 10 Correlated ETFs
NOTV
Top 10 Correlated Stocks
NOTV
In the News
NOTV Financial details
NOTV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
| Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.2 | 5.57 | 6.79 | 22.49 | 22.32 | |
| Net income per share | -0.08 | -0.43 | 0.83 | -13.85 | -4.1 | |
| Operating cash flow per share | 0.17 | 0.12 | 0.81 | -0.21 | 1.09 | |
| Free cash flow per share | -0.49 | -0.45 | -0.13 | -1.7 | 0.01 | |
| Cash per share | 0.06 | 0.13 | 10.53 | 0.76 | 1.38 | |
| Book value per share | 1.03 | 0.7 | 7.97 | 14.8 | 10.5 | |
| Tangible book value per share | 0.41 | -0.1 | 2.2 | -5.91 | -5.23 | |
| Share holders equity per share | 1.03 | 0.7 | 7.97 | 14.8 | 10.5 | |
| Interest debt per share | 1.66 | 3.49 | 13.33 | 17.09 | 17.97 | |
| Market cap | 37.27M | 51.87M | 385.7M | 410.36M | 78.97M | |
| Enterprise value | 53.3M | 86.87M | 420.97M | 778.34M | 461.12M | |
| P/E ratio | -47.18 | -11.07 | 35.4 | -1.22 | -0.75 | |
| Price to sales ratio | 0.85 | 0.86 | 4.3 | 0.75 | 0.14 | |
| POCF ratio | 20.98 | 40.21 | 35.89 | -78.66 | 2.83 | |
| PFCF ratio | -7.31 | -10.56 | -223.47 | -9.88 | 207.83 | |
| P/B Ratio | 3.48 | 6.83 | 3.67 | 1.14 | 0.29 | |
| PTB ratio | 3.48 | 6.83 | 3.67 | 1.14 | 0.29 | |
| EV to sales | 1.22 | 1.44 | 4.7 | 1.42 | 0.81 | |
| Enterprise value over EBITDA | -370.16 | -28.5 | 53.96 | -20.8 | 11.57 | |
| EV to operating cash flow | 30 | 67.34 | 39.17 | -149.19 | 16.54 | |
| EV to free cash flow | -10.45 | -17.69 | -243.9 | -18.75 | 1.21K | |
| Earnings yield | -0.02 | -0.09 | 0.03 | -0.82 | -1.33 | |
| Free cash flow yield | -0.14 | -0.09 | 0 | -0.1 | 0 | |
| Debt to equity | 1.55 | 4.79 | 1.66 | 1.07 | 1.55 | |
| Debt to assets | 0.4 | 0.59 | 0.54 | 0.4 | 0.49 | |
| Net debt to EBITDA | -111.31 | -11.48 | 4.52 | -9.83 | 9.59 | |
| Current ratio | 0.71 | 0.48 | 3.43 | 1.42 | 1.62 | |
| Interest coverage | -0.24 | -2.06 | 0.91 | -0.92 | -1.89 | |
| Income quality | -2.25 | -0.28 | 0.99 | 0.02 | -0.27 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.22 | 0.28 | 0.34 | 0.15 | 0.19 | |
| Research and developement to revenue | 0.01 | 0.02 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.15 | 0.14 | 0.24 | 0.52 | 0.47 | |
| Capex to operating cash flow | -3.87 | -4.81 | -1.16 | 6.96 | -0.99 | |
| Capex to revenue | -0.16 | -0.1 | -0.14 | -0.07 | -0.05 | |
| Capex to depreciation | -2.53 | -1.58 | -1.99 | -0.74 | -0.5 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.02 | 0.04 | 0.01 | |
| Graham number | 1.33 | 2.61 | 12.17 | 67.9 | 31.12 | |
| ROIC | -0.01 | -0.06 | 0.01 | -0.03 | -0.09 | |
| Return on tangible assets | -0.02 | -0.09 | 0.04 | -0.73 | -0.23 | |
| Graham Net | -2.21 | -4.07 | -4.26 | -19.46 | -17.9 | |
| Working capital | -5.06M | -16.34M | 133.91M | 68.88M | 81.61M | |
| Tangible asset value | 4.22M | -1.03M | 28.97M | -143.95M | -134.22M | |
| Net current asset value | -18.85M | -38.7M | -27.71M | -370.16M | -374.24M | |
| Invested capital | 1.55 | 4.79 | 1.66 | 1.07 | 1.55 | |
| Average receivables | 7.33M | 10.17M | 19.59M | 64.22M | 93.73M | |
| Average payables | 4.07M | 4.07M | 4.68M | 17.43M | 30.63M | |
| Average inventory | 1.14M | 897.5K | 651K | 36.02M | 63.77M | |
| Days sales outstanding | 79.67 | 65.33 | 115.54 | 66.7 | 55.72 | |
| Days payables outstanding | 58.75 | 27.62 | 37.84 | 26.83 | 29.2 | |
| Days of inventory on hand | 13.02 | 6.05 | 3.7 | 66.79 | 50.31 | |
| Receivables turnover | 4.58 | 5.59 | 3.16 | 5.47 | 6.55 | |
| Payables turnover | 6.21 | 13.21 | 9.65 | 13.61 | 12.5 | |
| Inventory turnover | 28.03 | 60.33 | 98.75 | 5.47 | 7.25 | |
| ROE | -0.07 | -0.62 | 0.1 | -0.94 | -0.39 | |
| Capex per share | -0.66 | -0.57 | -0.95 | -1.49 | -1.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.79 | 5.9 | 6.12 | 5.47 | 5.26 | |
| Net income per share | -3.4 | -0.37 | 0.07 | -0.38 | -0.6 | |
| Operating cash flow per share | -0.29 | 0.5 | 0.14 | 0.73 | -0.25 | |
| Free cash flow per share | -0.62 | 0.17 | -0.03 | 0.49 | -0.47 | |
| Cash per share | 0.81 | 0.96 | 0.86 | 1.38 | 0.85 | |
| Book value per share | 10.97 | 10.66 | 10.73 | 10.46 | 9.87 | |
| Tangible book value per share | -5.86 | -5.76 | -5.31 | -5.22 | -5.45 | |
| Share holders equity per share | 10.97 | 10.66 | 10.73 | 10.46 | 9.87 | |
| Interest debt per share | 16.34 | 16.64 | 16.67 | 16.66 | 15.6 | |
| Market cap | 126.48M | 111.22M | 122.71M | 79.27M | 94.55M | |
| Enterprise value | 513.57M | 503.48M | 518.61M | 461.42M | 501.07M | |
| P/E ratio | -0.36 | -2.89 | 16.67 | -2.05 | -1.54 | |
| Price to sales ratio | 1.03 | 0.73 | 0.78 | 0.56 | 0.7 | |
| POCF ratio | -17.07 | 8.67 | 33.22 | 4.22 | -14.45 | |
| PFCF ratio | -8.02 | 25.48 | -155.33 | 6.3 | -7.8 | |
| P/B Ratio | 0.45 | 0.41 | 0.44 | 0.29 | 0.37 | |
| PTB ratio | 0.45 | 0.41 | 0.44 | 0.29 | 0.37 | |
| EV to sales | 4.18 | 3.32 | 3.29 | 3.28 | 3.7 | |
| Enterprise value over EBITDA | -40.04 | 44.13 | 22.91 | 24.75 | 54.21 | |
| EV to operating cash flow | -69.31 | 39.22 | 140.39 | 24.59 | -76.56 | |
| EV to free cash flow | -32.55 | 115.35 | -656.46 | 36.67 | -41.35 | |
| Earnings yield | -0.69 | -0.09 | 0.01 | -0.12 | -0.16 | |
| Free cash flow yield | -0.12 | 0.04 | -0.01 | 0.16 | -0.13 | |
| Debt to equity | 1.45 | 1.52 | 1.51 | 1.55 | 1.54 | |
| Debt to assets | 0.47 | 0.48 | 0.49 | 0.49 | 0.47 | |
| Net debt to EBITDA | -30.18 | 34.38 | 17.49 | 20.5 | 43.98 | |
| Current ratio | 1.56 | 1.59 | 1.68 | 1.62 | 1.74 | |
| Interest coverage | -2.32 | -0.15 | 0.81 | 0.22 | -0.63 | |
| Income quality | 0.09 | -1.33 | 10.12 | -2.16 | 0.43 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.24 | 0.19 | 0.17 | 0.17 | 0.15 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.49 | 0.48 | 0.48 | 0.47 | 0.47 | |
| Capex to operating cash flow | 1.13 | -0.66 | -1.21 | -0.33 | 0.85 | |
| Capex to revenue | -0.07 | -0.06 | -0.03 | -0.04 | -0.04 | |
| Capex to depreciation | -0.63 | -0.65 | -0.32 | -0.42 | -0.34 | |
| Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 28.95 | 9.48 | 4.16 | 9.4 | 11.51 | |
| ROIC | -0.03 | 0 | 0 | 0 | -0.01 | |
| Return on tangible assets | -0.2 | -0.02 | 0 | -0.02 | -0.03 | |
| Graham Net | -18.62 | -18.83 | -18.2 | -17.83 | -17.73 | |
| Working capital | 76.4M | 78.19M | 81.91M | 81.61M | 81.2M | |
| Tangible asset value | -150.11M | -147.91M | -136.51M | -134.22M | -140.47M | |
| Net current asset value | -378.72M | -385.39M | -376.37M | -374.24M | -390.66M | |
| Invested capital | 1.45 | 1.52 | 1.51 | 1.55 | 1.54 | |
| Average receivables | 87.33M | 74.3M | 78.39M | 85.08M | 90.53M | |
| Average payables | 28.42M | 29.13M | 30.31M | 31.53M | 31.64M | |
| Average inventory | 73.54M | 69.96M | 59.1M | 55.01M | 60.26M | |
| Days sales outstanding | 54.69 | 43.98 | 47.31 | 55.88 | 62.22 | |
| Days payables outstanding | 25.07 | 25.44 | 26.82 | 30.2 | 23.77 | |
| Days of inventory on hand | 67.36 | 54.31 | 47.42 | 52.03 | 49.86 | |
| Receivables turnover | 1.65 | 2.05 | 1.9 | 1.61 | 1.45 | |
| Payables turnover | 3.59 | 3.54 | 3.36 | 2.98 | 3.79 | |
| Inventory turnover | 1.34 | 1.66 | 1.9 | 1.73 | 1.81 | |
| ROE | -0.31 | -0.04 | 0.01 | -0.04 | -0.06 | |
| Capex per share | -0.33 | -0.33 | -0.17 | -0.24 | -0.22 |
NOTV Frequently Asked Questions
What is Inotiv, Inc. stock symbol ?
Inotiv, Inc. is a US stock , located in West lafayette of In and trading under the symbol NOTV
What is Inotiv, Inc. stock quote today ?
Inotiv, Inc. stock price is $4.86 today.
Is Inotiv, Inc. stock public?
Yes, Inotiv, Inc. is a publicly traded company.
Company Profile
- Volume Average 429.89K
- Market Capitalization 153.71M
- Employee 1.96K
- CEO Mr. Robert W. Leasure Jr.
- Headquarters West Lafayette,IN,US
- IPO Date 1997-11-25
-
Website
https://www.inotivco.com 
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
